You are here: Home: CCU 4 | 2003: A CME Audio Series and Activity

Colorectal Cancer Update: A CME Audio Series and Activity

STATEMENT OF NEED / TARGET AUDIENCE

Colorectal cancer is among the most common cancers in the United States, and the arena of colorectal cancer treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and regimens and changes in indications, doses and schedules for existing treatments. In order to offer optimal patient care - including the option of clinical trial participation - the practicing medical oncologist must be well-informed of these advances.

To bridge the gap between research and patient care, Colorectal Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Describe ongoing clinical trials in colorectal cancer and their potential impact on patient care.
  
• Critically evaluate the clinical implications of emerging clinical trial data in colorectal cancer treatment.
  
• Develop and explain a management strategy for patients with colorectal cancer in the adjuvant and metastatic settings.
  

SPECIFIC LEARNING OBJECTIVES FOR ISSUE 4

Upon completion of this activity, participants should be able to:

• Describe the design and scientific rationale for the planned trial comparing infusional 5-FU, leucovorin and oxaliplatin to capecitabine and oxaliplatin with or without bevacizumab in patients with metastatic colorectal cancer.
  
• Develop a treatment strategy for patients with metastatic colorectal cancer that incorporates irinotecan, oxaliplatin, 5-FU and capecitabine.
  
• Review some of the ongoing clinical trials in pancreatic cancer and gastrointestinal stromal tumors (GIST).
  
• Consider the implications of the MOSAIC trial on the selection of adjuvant therapy for patients with colorectal cancer.
  
• Review the results from the Phase III trial evaluating IFL with or without bevacizumab in patients with metastatic disease.
  

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 2.75 category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent on the activity.